International study shows mavacamten monotherapy improves heart function in patients with HCM, a common inherited heart disease ...
When a young athlete suddenly dies of a heart attack, chances are high that they suffer from familial hypertrophic cardiomyopathy (HCM). Itis the most common genetic heart disease in the US and ...
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy ...
Edgewise Therapeutics, Inc., a leading muscle disease biopharmaceutical company, announced the dosing of the first patient in the phase 2 CIRRUS-HCM trial of EDG-7500. EDG-7500 is a novel oral, ...
The heart's ability to beat normally over a lifetime is predicated on the synchronized work of proteins embedded in the cells of the heart muscle. Like a fleet of molecular motors that get turned on ...
Research using heart cells from squirrels, mice and people identifies an evolutionary mechanism critical for heart muscle function. Research using heart cells from squirrels, mice and people ...
Everyday Health on MSN
How mavacamten (Camzyos) treats obstructive hypertrophic cardiomyopathy (HCM)
Taking the medication mavacamten for HCM can reduce obstruction in your heart. Learn about its benefits, risks, and side effects.
Research using heart cells from squirrels, mice and people identifies an evolutionary mechanism critical for heart muscle function. Gene defect that affects a protein found in the heart muscle ...
Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of the heart and a leading cause of sudden cardiac death in young people and athletes. Scientists have long known that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results